To Örebro University

oru.seÖrebro University Publications
Change search
Link to record
Permanent link

Direct link
Alternative names
Publications (10 of 141) Show all publications
Halkjær, S. I., Lo, B., Cold, F., Højer Christensen, A., Holster, S., König, J., . . . Petersen, A. M. (2023). Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. World Journal of Gastroenterology, 29(20), 3185-3202
Open this publication in new window or tab >>Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysis
Show others...
2023 (English)In: World Journal of Gastroenterology, ISSN 1007-9327, E-ISSN 2219-2840, Vol. 29, no 20, p. 3185-3202Article, review/survey (Refereed) Published
Abstract [en]

BACKGROUND; Irritable bowel syndrome (IBS) is the most prevalent gastrointestinal disorder in developed countries and reduces patients’ quality of life, hinders their ability to work, and increases health care costs. A growing number of trials have demonstrated an aberrant gut microbiota composition in IBS, also known as ‘gut dysbiosis’. Fecal microbiota transplantation (FMT) has been suggested as a treatment for IBS.

AIM: To assess the efficacy and safety of FMT for the treatment of IBS.

METHODS: We searched Cochrane Central, MEDLINE, EMBASE and Web of Science up to 24 October 2022 for randomised controlled trials (RCTs) investigating the effectiveness of FMT compared to placebo (including autologous FMT) in treating IBS. The primary outcome was the number of patients with improvements of symptoms measured using a validated, global IBS symptoms score. Secondary outcomes were changes in quality-of-life scores, non-serious and serious adverse events. Risk ratios (RR) and corresponding 95%CI were calculated for dichotomous outcomes, as were the mean differences (MD) and 95%CI for continuous outcomes. The Cochrane risk of bias tool was used to assess the quality of the trials. GRADE criteria were used to assess the overall quality of the evidence.

RESULTS: Eight RCTs (484 participants) were included in the review. FMT resulted in no significant benefit in IBS symptoms three months after treatment compared to placebo (RR 1.19, 95%CI: 0.68-2.10). Adverse events were reported in 97 participants in the FMT group and in 45 participants in the placebo group (RR 1.17, 95%CI: 0.63-2.15). One serious adverse event occurred in the FMT group and two in the placebo group (RR 0.42, 95%CI: 0.07-2.60). Endoscopic FMT delivery resulted in a significant improvement in symptoms, while capsules did not. FMT did not improve the quality of life of IBS patients but, instead, appeared to reduce it, albeit non significantly (MD -6.30, 95%CI: -13.39-0.79). The overall quality of the evidence was low due to moderate-high inconsistency, the small number of patients in the studies, and imprecision.

CONCLUSION: We found insufficient evidence to support or refute the use of FMT for IBS. Larger trials are needed

Place, publisher, year, edition, pages
Baishideng Publishing Group Inc., 2023
Keywords
Fecal microbiota transplantation, Irritable bowel syndrome, Meta-analysis, Systematic review
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-106103 (URN)10.3748/wjg.v29.i20.3185 (DOI)001020560400010 ()31662860 (PubMedID)2-s2.0-85162853635 (Scopus ID)
Available from: 2023-05-29 Created: 2023-05-29 Last updated: 2023-08-18
Forsgård, R. A., Rode, J., Lobenius Palmér, K., Kamm, A., Patil, S., Tacken, M. G. J., . . . Brummer, R. J. (2023). Limosilactobacillus reuteri DSM 17938 supplementation and SARS-CoV-2 specific antibody response in healthy adults: a randomized, triple-blinded, placebo-controlled trial. Gut microbes, 15(1), Article ID 2229938.
Open this publication in new window or tab >>Limosilactobacillus reuteri DSM 17938 supplementation and SARS-CoV-2 specific antibody response in healthy adults: a randomized, triple-blinded, placebo-controlled trial
Show others...
2023 (English)In: Gut microbes, ISSN 1949-0976, E-ISSN 1949-0984, Vol. 15, no 1, article id 2229938Article in journal (Refereed) Published
Abstract [en]

Studies have shown that probiotics can decrease the symptoms of respiratory tract infections as well as increase antibody responses following certain vaccinations. We examined the effect of probiotic supplementation on anti-SARS-CoV-2 specific antibody responses upon SARS-CoV-2 infection as well as after COVID-19 vaccination. In this randomized, triple-blinded, placebo-controlled intervention study with a parallel design, 159 healthy adults without prior SARS-CoV-2 infection or COVID-19 vaccination and any known risk factors for severe COVID-19 were randomly allocated into two study arms. The active treatment arm consumed a probiotic product containing a minimum of 1 × 108 colony-forming units of Limosilactobacillus reuteri DSM 17938 + 10 μg vitamin D3 twice daily for 6 months. The placebo arm consumed identical tablets containing only 10 μg vitamin D3. Anti-SARS-CoV-2 specific antibodies and virus neutralizing antibody titers were analyzed from blood samples collected at baseline, after 3 months, and after 6 months. Differences in serum antibody titers between the two study arms were tested with independent t-test using log-transformed values. In the intention-to-treat (ITT) analysis, SARS-CoV-2 infected individuals in the active treatment arm (n = 6) tended to have higher serum anti-spike IgG (609 [168-1480] BAU/ml vs 111 [36.1-1210] BAU/ml, p = 0.080) and anti-receptor binding domain (RBD) IgG (928 [212-3449] BAU/ml vs (83.7 [22.8-2094] BAU/ml, p = 0.066) levels than individuals in the placebo arm (n = 6). Considering individuals who were fully vaccinated with mRNA-based COVID-19 vaccines, the active treatment arm (n = 10) exhibited significantly higher serum levels of anti-RBD IgA (135 [32.9-976] BAU/ml vs 61.3 [26.7-97.1] BAU/ml, p = 0.036) than the placebo arm (n = 7) >28 days postvaccination. Supplementation with specific probiotics might improve the long-term efficacy of mRNA-based COVID-19 vaccines via enhanced IgA response.

Place, publisher, year, edition, pages
Taylor & Francis, 2023
Keywords
COVID-19, Probiotics, SARS-CoV-2, antibody, immunology
National Category
Infectious Medicine
Identifiers
urn:nbn:se:oru:diva-106943 (URN)10.1080/19490976.2023.2229938 (DOI)001020016900001 ()37401761 (PubMedID)2-s2.0-85164011823 (Scopus ID)
Available from: 2023-07-05 Created: 2023-07-05 Last updated: 2023-08-01Bibliographically approved
Kopp, L., Schweinlin, A., Tingö, L., Hutchinson, A. N., Feit, V., Jähnichen, T., . . . Bischoff, S. C. (2023). Potential Modulation of Inflammation and Physical Function by Combined Probiotics, Omega-3 Supplementation and Vitamin D Supplementation in Overweight/Obese Patients with Chronic Low-Grade Inflammation: A Randomized, Placebo-Controlled Trial. International Journal of Molecular Sciences, 24(10), Article ID 8567.
Open this publication in new window or tab >>Potential Modulation of Inflammation and Physical Function by Combined Probiotics, Omega-3 Supplementation and Vitamin D Supplementation in Overweight/Obese Patients with Chronic Low-Grade Inflammation: A Randomized, Placebo-Controlled Trial
Show others...
2023 (English)In: International Journal of Molecular Sciences, ISSN 1661-6596, E-ISSN 1422-0067, Vol. 24, no 10, article id 8567Article in journal (Refereed) Published
Abstract [en]

Obesity is characterized by low-grade inflammation and increased gut permeability. Here, we aim to evaluate the effect of a nutritional supplement on these parameters in subjects with overweight and obesity. A double-blinded, randomized clinical trial was conducted in 76 adults with overweight or obesity (BMI 28 to 40) and low-grade inflammation (high-sensitivity C-reactive protein (hs-CRP) between 2 and 10 mg/L). The intervention consisted of a daily intake of a multi-strain probiotic of Lactobacillus and Bifidobacterium, 640 mg of omega-3 fatty acids (n-3 FAs), and 200 IU of vitamin D (n = 37) or placebo (n = 39), administered for 8 weeks. hs-CRP levels did not change post-intervention, other than an unexpected slight increase observed in the treatment group. Interleukin (IL)-6 levels decreased in the treatment group (p = 0.018). The plasma fatty acid (FA) levels of the arachidonic acid (AA)/eicosapentaenoic acid (EPA) ratio and n-6/n-3 ratio (p < 0.001) decreased, and physical function and mobility improved in the treatment group (p = 0.006). The results suggest that hs-CRP may not be the most useful inflammatory marker, but probiotics, n-3 FAs, and vitamin D, as non-pharmaceutical supplements, may exert modest effects on inflammation, plasma FA levels, and physical function in patients with overweight and obesity and associated low-grade inflammation.

Place, publisher, year, edition, pages
MDPI, 2023
Keywords
obesity, overweight, chronic low-grade inflammation, probiotics, omega-3 fatty acids, hs-CRP
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
urn:nbn:se:oru:diva-106323 (URN)10.3390/ijms24108567 (DOI)000997365800001 ()37239916 (PubMedID)2-s2.0-85160373404 (Scopus ID)
Note

Funding agency:

Pfizer Consumer Healthcare

Available from: 2023-06-19 Created: 2023-06-19 Last updated: 2023-06-19Bibliographically approved
Bachmann, R., Van Hul, M., Baldin, P., Léonard, D., Delzenne, N. M., Belzer, C., . . . Cani, P. D. (2022). Akkermansia muciniphila Reduces Peritonitis and Improves Intestinal Tissue Wound Healing after a Colonic Transmural Defect by a MyD88-Dependent Mechanism. Cells, 11(17), Article ID 2666.
Open this publication in new window or tab >>Akkermansia muciniphila Reduces Peritonitis and Improves Intestinal Tissue Wound Healing after a Colonic Transmural Defect by a MyD88-Dependent Mechanism
Show others...
2022 (English)In: Cells, E-ISSN 2073-4409, Vol. 11, no 17, article id 2666Article in journal (Refereed) Published
Abstract [en]

Anastomotic leakage is a major complication following colorectal surgery leading to peritonitis, complications, and mortality. Akkermansia muciniphila has shown beneficial effects on the gut barrier function. Whether A. muciniphila reduces peritonitis and mortality during colonic leakage is unknown. Whether A. muciniphila can directly modulate the expression of genes in the colonic mucosa in humans has never been studied. We investigated the effects of a pretreatment (14 days) with live A. muciniphila prior to surgical colonic perforation on peritonitis, mortality, and wound healing. We used mice with an inducible intestinal-epithelial-cell-specific deletion of MyD88 (IEC-MyD88 KO) to investigate the role of the innate immune system in this context. In a proof-of-concept pilot study, healthy humans were exposed to A. muciniphila for 2 h and colonic biopsies taken before and after colonic instillation for transcriptomic analysis. Seven days after colonic perforation, A.-muciniphila-treated mice had significantly lower mortality and severity of peritonitis. This effect was associated with significant improvements of wound histological healing scores, higher production of IL22, but no changes in the mucus layer thickness or genes involved in cell renewal, proliferation, or differentiation. All these effects were abolished in IEC-MyD88 KO mice. Finally, human subjects exposed to A. muciniphila exhibited an increased level of the bacterium at the mucus level 2 h after instillation and significant changes in the expression of different genes involved in the regulation of cell cycling, gene transcription, immunity, and inflammation in their colonic mucosa. A. muciniphila improves wound healing during transmural colonic wall defect through mechanisms possibly involving IL22 signaling and requiring MyD88 in the intestinal cells. In healthy humans, colonic administration of A. muciniphila is well tolerated and changes the expression of genes involved in the immune pathways.

Place, publisher, year, edition, pages
MDPI, 2022
Keywords
Akkermansia muciniphila, Myd88, colonic leakage, peritonitis, wound healing
National Category
Immunology
Identifiers
urn:nbn:se:oru:diva-101170 (URN)10.3390/cells11172666 (DOI)000851017500001 ()36078075 (PubMedID)2-s2.0-85137845423 (Scopus ID)
Note

Funding agencies:

Fonds de la Recherche Scientifique - FNRS FNRS T.0030.21 J.0027.22 WELBIO-CR-2022A-02 WELBIO-CR-2019C-02R 30770923 40007505  

Netherlands Organization for Scientific Research (NWO) 024.002.002

Available from: 2022-09-12 Created: 2022-09-12 Last updated: 2023-12-08Bibliographically approved
van der Geest, A. M., Schukking, I., Brummer, R. J., van de Burgwal, L. H. & Larsen, O. F. (2022). Comparing probiotic and drug interventions in irritable bowel syndrome: a meta-analysis of randomised controlled trials. Beneficial Microbes, 13(3), 183-194
Open this publication in new window or tab >>Comparing probiotic and drug interventions in irritable bowel syndrome: a meta-analysis of randomised controlled trials
Show others...
2022 (English)In: Beneficial Microbes, ISSN 1876-2883, E-ISSN 1876-2891, Vol. 13, no 3, p. 183-194Article, review/survey (Refereed) Published
Abstract [en]

Clinical decisions made by health professionals to recommend either drug or probiotic interventions for irritable bowel syndrome (IBS) should be supported by proper knowledge of the efficacy rates of both types of interventions. In this article, we performed a systematic review and meta-analysis to examine the efficacy of both probiotic- and drug interventions in IBS. Medline was searched between January 2015 - January 2021. Randomised controlled trials (RCT) recruiting participants > 18 years old with IBS and examining the effect of probiotics or drugs were eligible for inclusion. The data of the primary outcome, i.e. the persistence of IBS symptoms (dichotomous symptom data), were pooled to obtain a relative risk (RR), with a 95% confidence interval (CI). Secondary outcomes, abdominal pain- and bloating scores (continuous data), were pooled using a standardised mean difference with a 95% CI. The search identified 269 citations of which 32 RCTs were eligible. Our meta-analysis indicated that both probiotic and drug interventions are able to improve the persistence of IBS symptoms (RR 0.60 [0.51; 0.92] versus 0.87 [0.81; 0.92], respectively) and abdominal pain scores (standardised mean difference (SMD) -0.35 [-0.56; -0.14] versus -0.10 [-0.20; 0.00], respectively). However, determining the overall efficacy of both intervention types is inherently complex and such results should be interpreted with care, due to the large diversity of probiotic- and drug types and doses, which is also complicated by variety in IBS subtypes. Hence, as a first step, more large scale randomised double blind placebo-controlled trials focussing on a specific IBS subtype targeted with specific probiotic strains or specific pharmaceutical modalities should be executed, enabling a more proper comparison between trials.

Place, publisher, year, edition, pages
Wageningen Academic Publishers, 2022
Keywords
Burden to benefit ratio, drugs, efficacy, probiotics
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-100579 (URN)10.3920/BM2021.0123 (DOI)000837954700002 ()35848115 (PubMedID)2-s2.0-85135596470 (Scopus ID)
Available from: 2022-08-15 Created: 2022-08-15 Last updated: 2022-08-30Bibliographically approved
Stenberg, R., Brummer, R. J. & Norén, T. (2022). Faecal transplantation in a 2-year-old child with therapy-resistant Clostridiodes difficile infection. Acta Paediatrica, 111(8), 1628-1629
Open this publication in new window or tab >>Faecal transplantation in a 2-year-old child with therapy-resistant Clostridiodes difficile infection
2022 (English)In: Acta Paediatrica, ISSN 0803-5253, E-ISSN 1651-2227, Vol. 111, no 8, p. 1628-1629Article in journal (Refereed) Published
Place, publisher, year, edition, pages
Wiley-Blackwell Publishing Inc., 2022
National Category
Infectious Medicine
Identifiers
urn:nbn:se:oru:diva-98655 (URN)10.1111/apa.16363 (DOI)000786539600001 ()35434820 (PubMedID)2-s2.0-85128693979 (Scopus ID)
Available from: 2022-04-21 Created: 2022-04-21 Last updated: 2022-08-22Bibliographically approved
Fart, F., Tingö, L., Engelheart, S., Lindqvist, C. M., Brummer, R. J., Kihlgren, A. & Schoultz, I. (2022). Gut Health and Its Association with Wellbeing and Nutrient Intake in Community-Dwelling Older Adults. Gastroenterology Insights, 13(4), 349-364
Open this publication in new window or tab >>Gut Health and Its Association with Wellbeing and Nutrient Intake in Community-Dwelling Older Adults
Show others...
2022 (English)In: Gastroenterology Insights, ISSN 2036-7414, E-ISSN 2036-7422, Vol. 13, no 4, p. 349-364Article in journal (Refereed) Published
Abstract [en]

Many of the increasing number of community-dwelling older adults will need increased healthcare in the future. By characterising gut health and its association with wellbeing and nutrient intake in this population, we aim to recognise areas along the gut-brain axis through which the health of community-dwelling older adults might be promoted. In this cross-sectional observational study, validated questionnaires were used to assess gut health, nutrient intake, and wellbeing in 241 community-dwelling older adults (>= 65 years old). In total, 65% of the participants experienced at least one gastrointestinal symptom, of which females had more abdominal pain and constipation, while the oldest old (i.e., >= 80 years old) had more diarrhoea. Increased gastrointestinal symptoms correlated with more stress, anxiety, depression, and a decreased quality of life, in addition to dyspepsia which correlated with a lower E% of protein. Most of the participants did not reach the recommended intake for protein, fibre and polyunsaturated fats. Males had a lower intake of protein (E%) and fibre (g/MJ) than females, and the oldest old had a lower E% of protein than younger older adults. In conclusion, our results demonstrate that gastrointestinal symptoms are common, and most of the study participants had an imbalanced macronutrient intake, which could be a target for future possible dietary interventions to improve overall health.

Place, publisher, year, edition, pages
MDPI, 2022
Keywords
gastrointestinal symptoms, elderly, dietary intake, general health
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-103229 (URN)10.3390/gastroent13040035 (DOI)000902519200001 ()2-s2.0-85144691540 (Scopus ID)
Funder
Knowledge Foundation, 20110225
Note

Funding agencies:

Bo Rydins stiftelse F0514

Faculty of Medicine and Health at Örebro University

Available from: 2023-01-19 Created: 2023-01-19 Last updated: 2023-01-23Bibliographically approved
van der Geest, A. M., Schukking, I., Brummer, R. J., Pieterse, H., van den Nieuwboer, M., van de Burgwal, L. H. & Larsen, O. F. (2022). Inadequate safety reporting in the publications of randomised clinical trials in irritable bowel syndrome: drug versus probiotic interventions. Beneficial Microbes, 13(3), 195-204
Open this publication in new window or tab >>Inadequate safety reporting in the publications of randomised clinical trials in irritable bowel syndrome: drug versus probiotic interventions
Show others...
2022 (English)In: Beneficial Microbes, ISSN 1876-2883, E-ISSN 1876-2891, Vol. 13, no 3, p. 195-204Article, review/survey (Refereed) Published
Abstract [en]

Randomised controlled clinical trials (RCTs) offer a unique opportunity to obtain controlled efficacy and safety data to support clinical decisions. However, most RCT reporting has a stronger focus on efficacy rather than safety. This study aimed to identify the safety profile of both probiotic and drug interventions in irritable bowel syndrome (IBS). In connection to this paper, an accompanying paper was published in which a meta-analysis was conducted to evaluate the efficacy of probiotic interventions compared to that of drug interventions in IBS. Together, these two studies provide a first assessment regarding the feasibility to determine a burden to benefit ratio for both probiotic and drug interventions in IBS. RCTs including participants (>18 years old) with IBS and comparing probiotic or drugs interventions with control groups were identified by a systematic search of MEDLINE (January 2015 - Jan 2021). Reported safety profiles in drug studies were completer and more detailed as compared with studies on probiotics. Several inconsistencies in safety reporting were identified between and within drug and probiotic studies, such as: didn't report on safety; only reported adverse reactions (ARs) or adverse events (AEs) with a certain severity; didn't report the total number of AEs; didn't split in the control- or experimental arm; didn't specify AEs; and used different thresholds for 'common' AEs. Hence, it is difficult to compare safety data from drug and probiotic RCTs across and between different studies. On the current approaches to safety reporting, we could not establish an unambiguous safety profile for neither probiotic and drug interventions in IBS. These shortcomings hamper a critical comparison of the burden to benefit ratio for IBS intervention.

Place, publisher, year, edition, pages
Wageningen Academic Publishers, 2022
Keywords
Adverse events, burden to benefit ratio, safety profile
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-100585 (URN)10.3920/BM2021.0124 (DOI)000837954700003 ()35848114 (PubMedID)2-s2.0-85135597400 (Scopus ID)
Available from: 2022-08-15 Created: 2022-08-15 Last updated: 2022-08-29Bibliographically approved
Rode, J., Edebol Carlman, H. M. T., König, J., Hutchinson, A., Thunberg, P., Persson, J. & Brummer, R. J. (2022). Multi-Strain Probiotic Mixture Affects Brain Morphology and Resting State Brain Function in Healthy Subjects: An RCT. Cells, 11(18), Article ID 2922.
Open this publication in new window or tab >>Multi-Strain Probiotic Mixture Affects Brain Morphology and Resting State Brain Function in Healthy Subjects: An RCT
Show others...
2022 (English)In: Cells, E-ISSN 2073-4409, Vol. 11, no 18, article id 2922Article in journal (Refereed) Published
Abstract [en]

Probiotics can alter brain function via the gut-brain axis. We investigated the effect of a probiotic mixture containing Bifidobacterium longum, Lactobacillus helveticus and Lactiplantibacillus plantarum. In a randomized, placebo-controlled, double-blinded crossover design, 22 healthy subjects (6 m/16 f; 24.2 ± 3.4 years) underwent four-week intervention periods with probiotics and placebo, separated by a four-week washout period. Voxel-based morphometry indicated that the probiotic intervention affected the gray matter volume of a cluster covering the left supramarginal gyrus and superior parietal lobule (p &lt; 0.0001), two regions that were also among those with an altered resting state functional connectivity. Probiotic intervention resulted in significant (FDR &lt; 0.05) functional connectivity changes between regions within the default mode, salience, frontoparietal as well as the language network and several regions located outside these networks. Psychological symptoms trended towards improvement after probiotic intervention, i.e., the total score of the Hospital Anxiety and Depression Scale (p = 0.056) and its depression sub-score (p = 0.093), as well as sleep patterns (p = 0.058). The probiotic intervention evoked distinct changes in brain morphology and resting state brain function alongside slight improvements of psycho(bio)logical markers of the gut-brain axis. The combination of those parameters may provide new insights into the modes of action by which gut microbiota can affect gut-brain communication and hence brain function.

Place, publisher, year, edition, pages
MDPI, 2022
Keywords
CO2 inhalation challenge, autonomic nervous system, brain-derived neurotrophic factor (BDNF), cortisol awakening response, gut microbiota, mental health, resting state functional connectivity, serotonin, sleep quality, structural changes
National Category
Neurology
Identifiers
urn:nbn:se:oru:diva-101446 (URN)10.3390/cells11182922 (DOI)000858164900001 ()36139496 (PubMedID)2-s2.0-85138356660 (Scopus ID)
Note

Funding agencies:

Global Medical Innovation

Pfizer Consumer Healthcare

General Electric 20150081

Available from: 2022-09-24 Created: 2022-09-24 Last updated: 2022-10-05Bibliographically approved
Tingö, L., Hutchinson, A. N., Bergh, C., Stiefvatter, L., Schweinlin, A., Jensen, M. G., . . . Brummer, R. J. (2022). Potential Modulation of Inflammation by Probiotic and Omega-3 Supplementation in Elderly with Chronic Low-Grade Inflammation-A Randomized, Placebo-Controlled Trial. Nutrients, 14(19), Article ID 3998.
Open this publication in new window or tab >>Potential Modulation of Inflammation by Probiotic and Omega-3 Supplementation in Elderly with Chronic Low-Grade Inflammation-A Randomized, Placebo-Controlled Trial
Show others...
2022 (English)In: Nutrients, E-ISSN 2072-6643, Vol. 14, no 19, article id 3998Article in journal (Refereed) Published
Abstract [en]

Probiotic and omega-3 supplements have been shown to reduce inflammation, and dual supplementation may have synergistic health effects. We investigated if the novel combination of a multi-strain probiotic (containing B. lactis Bi-07, L. paracasei Lpc-37, L. acidophilus NCFM, and B. lactis Bl-04) alongside omega-3 supplements reduces low-grade inflammation as measured by high-sensitivity C-reactive protein (hs-CRP) in elderly participants in a proof-of-concept, randomized, placebo-controlled, parallel study (NCT04126330). In this case, 76 community-dwelling elderly participants (median: 71.0 years; IQR: 68.0-73.8) underwent an intervention with the dual supplement (n = 37) or placebo (n = 39) for eight weeks. In addition to hs-CRP, cytokine levels and intestinal permeability were also assessed at baseline and after the eight-week intervention. No significant difference was seen for hs-CRP between the dual supplement group and placebo. However, interestingly, supplementation did result in significant increases in the level of the anti-inflammatory marker IL-10. In addition, dual supplementation increased levels of valeric acid, further suggesting the potential of the supplements in reducing inflammation and conferring health benefits. Together, the results suggest that probiotic and omega-3 dual supplementation exerts modest effects on inflammation and may have potential use as a non-pharmacological treatment for low-grade inflammation in the elderly.

Place, publisher, year, edition, pages
MDPI, 2022
Keywords
RCT, chronic low-grade inflammation, elderly, hs-CRP, n-3 PUFA, omega-3, probiotics, short-chain fatty acids
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-101799 (URN)10.3390/nu14193998 (DOI)000866959300001 ()36235651 (PubMedID)2-s2.0-85139781366 (Scopus ID)
Note

Funding agency:

Pfizer Consumer Healthcare

Available from: 2022-10-17 Created: 2022-10-17 Last updated: 2023-08-28Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-0362-0008

Search in DiVA

Show all publications